The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.

Hely, M. A.; Morris, J. Glenn; Reid, Wayne G.J.; O'sullivan, D. J.; Williamson, Peter; Rail, David; Broe, G. A.; Margrie, S.

doi:10.1136/jnnp.57.8.903

Cited by 145 publications

(141 citation statements)

References 25 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Likewise, the moderate and unchanged level of the lisuride dosage (average 1 mg/day) shows that, by tapering in by 0.1 mg graduations per week and with a good understanding of the expected undesirable effects, the investigators rapidly found what appeared to them as the optimal dosage. The observed undesirable effects (psychiatric effects including sleep disorders, digestive disorders such as nausea and vomiting at treatment onset) were in agreement with published data concerning dopaminergic agonists [22, 23, 24, 25, 26, 27, 28]. …”

Section: Discussionsupporting

confidence: 80%

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

et al. 2000

View full text Add to dashboard Cite

The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson’s disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson’s disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson’s Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p < 0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.

show abstract

Section: Discussionsupporting

confidence: 80%

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Clinical studies randomly assigning patients to initial treatment with a dopamine agonist or levodopa have shown a lower risk for dyskinesias in the agonist-treated groups (agonists studied have included pramipexole [22, 61], ropinirole [23, 62], bromocriptine [63, 64], pergolide [65], and cabergoline [21]). Retrospective analyses have demonstrated that once levodopa is added, the rate of development of dyskinesias is the same regardless of whether or not the patient was already taking a dopamine agonist [62, 66].…”

Section: Pharmacologic Strategies To Directly Address the Incidence Omentioning

confidence: 99%

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

Encarnacion¹,

Hauser

2008

Eur Neurol

View full text Add to dashboard Cite

Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson’s disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

show abstract

“…However, during long-term use of L-dopa, many patients with Parkinson's disease develop motor response fluctuations that, in many cases, force treatment discontinuation (eg, wearing off, on-off fluctuations, night-time deterioration, early morning worsening, and dyskinesias). 9,10 These side effects have been linked to fluctuations of striatal dopamine levels during intermittent L-dopa therapy, and some success in reducing them has been obtained with the use of slow-release L-dopa formulations. 11 The currently available pharmacologic and nonpharmacologic treatments are capable of offering only symptomatic relief for patients.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

López¹,

Bata-García²,

Esquivel³

et al. 2010

IJN

View full text Add to dashboard Cite

Introduction We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions with the silica surface. Methods Several samples were prepared by varying the wt% of dopamine added during the hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by N 2 adsorption, scanning and transmission electron microscopy, and Fourier transform infrared spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m 2 /g nanostructured silica materials. The stability of dopamine in the silica network was confirmed by infrared and 13 C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated by means of apomorphine-induced rotation behavior in hemiparkisonian rats. Results The in vitro dopamine delivery profiles indicate two regimes of release, a fast and sustained dopamine delivery was observed up to 24 hours, and after this time the rate of delivery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while implants without dopamine were always translucent. Conclusion The major finding of the study was that intrastriatal silica–dopamine implants reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals implanted with silica or silica–dopamine.

show abstract

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.

Abstract: 149 previously untreated patients with Parkinson's disease were recruited over a three year period and randomly allocated to either low dose levodopa-carbidopa

Cited by 145 publications

References 25 publications

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

Contact Info

Product

Resources

About

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.

Abstract: 149 previously untreated patients with Parkinson's disease were recruited over a three year period and randomly allocated to either low dose levodopa-carbidopa

Cited by 145 publications

References 25 publications

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

Treatment of Parkinson's disease: nanostructured sol&ndash;gel silica&ndash;dopamine reservoirs for controlled drug release in the central nervous system

Contact Info

Product

Resources

About

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system